Ингибирование теломеразы человека (1105569), страница 17
Текст из файла (страница 17)
2012. V. 8.P. e1002805.Mergny J.L., Riou J.F., Mailliet P., Teulade-Fichou M.P., Gilson E. Naturaland pharmacological regulation of telomerase. // Nucleic Acids Res. 2002. V.30. P. 839-865.Fletcher T.M., Cathers B.E., Ravikumar K.S., Mamiya B.M., Kerwin S.M.Inhibition of human telomerase by 7-deaza-2'-deoxyguanosine nucleosidetriphosphate analogs: potent inhibition by 6-thio-7-deaza-2'-deoxyguanosine5'-triphosphate. // Bioorg Chem. 2001. V.
29. P. 36-55.Grulich A.E., van Leeuwen M.T., Falster M.O., Vajdic C.M. Incidence of123[59][60][61][62][63][64][65][66][67][68][69][70]cancers in people with HIV/AIDS compared with immunosuppressedtransplant recipients: a meta-analysis. // Lancet. 2007.
V. 370. P. 59-67.Chaturvedi A.K., Madeleine M.M., Biggar R.J., Engels E.A. Risk of humanpapillomavirus-associated cancers among persons with AIDS. // Journal ofthe National Cancer Institute. 2009. V. 101. P. 1120–1130.Engels E.A., Biggar R.J., Hall H.I., Cross H., Crutchfield A., Finch J.L.,Grigg R., Hylton T., Pawlish K.S., McNeel T.S., Goedert J.J. Cancer risk inpeople infected with human immunodeficiency virus in the United States.
//International Journal of Cancer. 2008. V. 123. P. 187–194.Engels E.A., Pfeiffer RM., Goedert J.J., Virgo P., McNeel T.S., Scoppa S.M.,Biggar R.J. Trends in cancer risk among people with AIDS in the UnitedStates 1980–2002. // AIDS. 2006. V. 20. P. 1645-1654.Sauerwald A., Sandin S., Cristofari G., Scheres S.H., Lingner J., Rhodes D.Structure of active dimeric human telomerase. // Nat Struct Mol Biol. 2013. V.20. P. 454-460.El-Daly H., Kull M., Zimmermann S., Pantic M., Waller C.F., Martens U.M.Selective cytotoxicity and telomere damage in leukemia cells using thetelomerase inhibitor BIBR1532. // Blood. 2005.
V. 104. P. 1742-1749.Gryaznov S. US Patent No. 7,494,982 (24 February 2009).Gryaznov S.M. Oligonucleotide N3’-P5’ Phosphoramidates and ThioPhoshoramidates as Potential Therapeutic Agents. // Chemistry &Biodiversity. 2010. V. 7. P. 477-493.Url: http://clinicaltrials.gov/ct2/show/NCT01137968?term=Geron&rank=8Url: http://ir.geron.com/phoenix.zhtml?c=67323&p=irolnewsArticle&ID=1733274Thompson P.A., Drissi R., Muscal J.A., Panditharatna E., Fouladi M., IngleA.M., Ahern C.H., Reid J.M., Lin T., Weigel B.J., Blaney S.M.
A phase I trialof imetelstat in children with refractory or recurrent solid tumors: a Children'sOncology Group Phase I Consortium Study (ADVL1112). // Clin Cancer Res.2013. V. 19. P. 6578-6584.Tefferi A., Begna K., Laborde R., Patnaik M., Lasho T., Zblewski D., FinkeC., Schimek L., LaPlant B., Hanson C., Stuart M., Pardanani A. Imetelstat, aTelomerase Inhibitor, Induces Morphologic and Molecular Remissions InMyelofibrosis and Reversal Of Bone Marrow Fibrosis. // 55th ASH AnnualMeeting.
2013. # 662.Gryaznov S.M., Lloyd D.H. Modulation of oligonucleotide duplex and triplexstability via hydrophobic interactions. // Nucleic Acids Res. 1993. V. 21. P.5909-5915.124[71][72][73][74][75][76][77][78][79][80]Jackson S.R., Zhu C.H., Paulson V., Watkins L., Dikmen Z.G., GryaznovS.M., Wright W.E., Shay J.W. Antiadhesive effects of GRN163L--anoligonucleotide N3'->P5' thio-phosphoramidate targeting telomerase. //Cancer Res.
2007. V. 67. P. 1121-1129.Mender I., Senturk S., Ozgunes N., Akcali K.C., Kletsas D., Gryaznov S.,Can A., Shay J.W., Dikmen Z.G. Imetelstat (a telomerase antagonist) exertsoff-target effects on the cytoskeleton. // International Journal Of Oncology.2013. V. 42. P. 1709-1715.Asai A., Oshima Y., Yamamoto Y., Uochi T.A., Kusaka H., Akinaga S.,Yamashita Y., Pongracz K., Pruzan R., Wunder E., Piatyszek M., Li S., ChinA.C., Harley C.B., Gryaznov S. A novel telomerase template antagonist(GRN163) as a potential anticancer agent. // Cancer Res. 2003. V. 63. P.3931-3939.Canales B.K., Li Y., Thompson M.G., Gleason J.M., Chen Z., Malaeb B.,Corey D.R., Herbert B.S., Shay J.W., Koeneman K.S. Small molecule,oligonucleotide-based telomerase template inhibition in combination withcytolytic therapy in an in vitro androgen-independent prostate cancer model.
//Urol Oncol. 2006. V. 24. P. 141-151.Bennett C., Ecker D., Vickers T., Wyatt J. US Patent No. US20070270363 A1(22 November 2007).Rankin A.M., Faller D.V., Spanjaard R.A. Telomerase inhibitors and 'T-oligo'as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity. //Anticancer Drugs. 2008. V. 19. P. 329-338.Meyerson M., Counter C.M., Eaton E.N., Ellisen L.W., Steiner P., CaddleS.D., Ziaugra L., Beijersbergen R.L., Davidoff M.J., Liu Q., Bacchetti S.,Haber D.A., Weinberg R.A. hEST2, the putative human telomerase catalyticsubunit gene, is up-regulated in tumor cells and during immortalization. //Cell. 1997.
V. 90. P. 785-795.Glasspool R.M., Burns S., Hoare S.F., Svensson C., Keith W.N. The hTERTand hTERC telomerase gene promoters are activated by the second exon ofthe adenoviral protein, E1A, identifying the transcriptional corepressor CtBPas a potential repressor of both genes. // Neoplasia. 2005. V. 7. P.
614-622.Moon D.O., Kim M.O., Lee J.D., Choi Y.H., Kim G.Y. Butein suppresses cMyc-dependent transcription and Akt-dependent phosphorylation of hTERTin human leukemia cells. // Cancer Lett. 2009. V. 286. P. 172-179.Guo Q.L., Lin S.S., You Q.D., Gu H.Y., Yu J., Zhao L., Qi Q., Liang F., TanZ., Wang X. Inhibition of human telomerase reverse transcriptase geneexpression by gambogic acid in human hepatoma SMMC-7721 cells.
// LifeSci. 2006. V. 78. P. 1238-1245.125[81][82][83][84][85][86][87][88][89][90][91][92]Jagadeesh S., Kyo S., Banerjee P.P. Genistein represses telomerase activityvia both transcriptional and posttranslational mechanisms in human prostatecancer cells.
// Cancer Res. 2006. V. 66. P. 2107-2115.Kyo S., Takakura M., Taira T., Kanaya T., Itoh H., Yutsudo M., Ariga H.,Inoue M. Sp1 cooperates with c-Myc to activate transcription of the humantelomerase reverse transcriptase gene (hTERT). // Nucleic Acids Res. 2000. V.28. P. 669-677.Shapira S., Granot G., Mor-Tzuntz R., Raanani P., Uziel O., Lahav M.,Shpilberg O. Second-generation tyrosine kinase inhibitors reduce telomeraseactivity in K562 cells. // Cancer Lett.
2012. V. 323. P. 223-231.Nanni S., Narducci M., Della Pietra L., Moretti F., Grasselli A., De Carli P.,Sacchi A., Pontecorvi A., Farsetti A. Signaling through estrogen receptorsmodulates telomerase activity in human prostate cancer. // J Clin Invest. 2002.V. 110.
P. 219-227.Aldous W.K., Marean A.J., DeHart M.J., Matej L.A., Moore K.H. Effects oftamoxifen on telomerase activity in breast carcinoma cell lines. // Cancer.1999. V. 85. P. 1523-1529.Sekaran V., Soares J., Jarstfer M.B. Telomere maintenance as a target fordrug discovery. // J Med Chem. 2014. V. 57. P. 521-538.Li H., Zhao L.L., Funder J.W., Liu J.P. Protein phosphatase 2A inhibitsnuclear telomerase activity in human breast cancer cells. // J Biol Chem.
1997.V. 272. P. 16729-16732.Yu C.C., Lo S.C., Wang T.C. Telomerase is regulated by protein kinase Czeta in human nasopharyngeal cancer cells. // Biochem J. 2001. V. 355. P.459-464.Kim Y.W., Hur S.Y., Kim T.E., Lee J.M., Namkoong S.E., Ki I.K., Kim J.W.Protein kinase C modulates telomerase activity in human cervical cancer cells.// Exp Mol Med. 2001. V. 33. P. 156-163.Uziel O., Fenig E., Nordenberg J., Beery E., Reshef H., Sandbank J.,Birenbaum M., Bakhanashvili M., Yerushalmi R., Luria D., Lahav M.Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibitsproliferation in telomerase-expressing cell lines.
// Br J Cancer. 2005. V. 92.P. 1881-1891.Chung J., Khadka P., Chung I.K. Nuclear import of hTERT requires abipartite nuclear localization signal and Akt-mediated phosphorylation. // JCell Sci. 2012. V. 125. P. 2684-2697.Kang S.S., Kwon T., Kwon D.Y., Do S.I. Akt protein kinase enhances humantelomerase activity through phosphorylation of telomerase reverse126[93][94][95][96][97][98][99][100][101][102][103][104]transcriptase subunit. // J Biol Chem.
1999. V. 274. P. 13085-13090.Neidle S. Therapeutic Applications of Quadruplex Nucleic Acids. // Elsevier,2012.Zahler A.M., Williamson J.R., Cech T.R., Prescott D.M. Inhibition oftelomerase by G-quartet DNA structure. // Nature. 1991. V. 350. P. 718-720.Neidle S. Human telomeric G-quadruplex: The current status of telomeric Gquadruplexes as therapeutic targets in human cancer. // FEBS Journal. 2009.V.
277. P. 1118-1125.Draskovic I., Londono Vallejo A. Telomere recombination and alternativetelomere lengthening mechanisms. // Front Biosci (Landmark Ed). 2013. V.18. P. 1-20.Li Q., Xiang J.F., Yang Q.F., Sun H.X., Guan A.J., Tang Y.L. G4LDB: adatabase for discovering and studying G-quadruplex ligands. // Nucleic AcidsResearch. 2013. V. 41.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
